Here's our price objective.
The potential buy trades are in Invitae Corp. and Salesforce.com.
Let's check out the charts and technical indicators.
T2 Biosystems and Tyme Technologies have both perked up of late after languishing for extended periods of time.
The technical indicators are mixed for the big medical device maker and suggest bulls are not strongly behind the latest advance in the shares.
A correction in EBS could soon set up an attractive opportunity.
The $180 area is our intermediate-term price objective.
Our latest analysis and trading strategy for the cloud healthcare software provider.
The shares have climbed nearly five-fold from their Covid nadir.
Consider adding or going long above this critical price level.